{"name": "Galectin Therapeutics",
 "permalink": "pro-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/pro-pharmaceuticals",
 "homepage_url": "http://www.galectintherapeutics.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "GalectinGALT",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2000,
 "founded_month": 12,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "foley@galectintherapeutics.com",
 "phone_number": "617-559-0033",
 "description": "",
 "created_at": "Fri Dec 11 06:49:01 UTC 2009",
 "updated_at": "Fri Mar 29 04:04:16 UTC 2013",
 "overview": "\u003Cp\u003EGalectin Therapeutics, Inc., a development stage company, engages in the discovery and development of carbohydrate-based therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. Its lead product candidate in development, GM-CT-01, is a proprietary polysaccharide galectin inhibitor, which has completed Phase II trials for the treatment of colorectal cancer in combination with 5-FU, a chemotherapy for the treatment of various types of cancer. \u003C/p\u003E\n\n\u003Cp\u003EThe company has research collaborations with the Mount Sinai School of Medicine to study the anti-fibrotic effects of its carbohydrate compounds on liver fibrosis; with Brigham and Women\u00e2\u20ac\u2122s Hospital to evaluate the anti-fibrotic effects of these compounds to treat acute and chronic kidney disease; and with the Ludwig Institute in Brussels, Belgium to show whether inhibiting the action of galectin-3 improves the efficacy of T lymphocytes in killing tumor cells. \u003C/p\u003E\n\n\u003Cp\u003EGalectin Therapeutics (previously Pro-Pharmaceuticals) was founded in December 2000 and is based in Newton, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       36],
      "assets/images/resized/0006/9262/69262v4-max-150x150.jpg"],
     [[250,
       60],
      "assets/images/resized/0006/9262/69262v4-max-250x250.jpg"],
     [[267,
       65],
      "assets/images/resized/0006/9262/69262v4-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Founder and Executive Chairman, Board of Directors",
    "person":
     {"first_name": "James",
      "last_name": "Czirr",
      "permalink": "james-czirr",
      "image": null}},
   {"is_past": false,
    "title": "Founder and Chief Scientist",
    "person":
     {"first_name": "Anatole",
      "last_name": "Klyosov",
      "permalink": "anatole-klyosov",
      "image": null}},
   {"is_past": false,
    "title": "President and CEO, Board of Directors",
    "person":
     {"first_name": "Peter",
      "last_name": "G. Traber",
      "permalink": "peter-g-traber",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Maureen",
      "last_name": "Foley",
      "permalink": "maureen-foley",
      "image": null}},
   {"is_past": false,
    "title": "Vice Chairman, Board of Directors",
    "person":
     {"first_name": "Rod",
      "last_name": "D. Martin",
      "permalink": "rod-martin",
      "image":
       {"available_sizes":
         [[[150,
            105],
           "assets/images/resized/0015/3339/153339v2-max-150x150.jpg"],
          [[250,
            175],
           "assets/images/resized/0015/3339/153339v2-max-250x250.jpg"],
          [[318,
            223],
           "assets/images/resized/0015/3339/153339v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Gilbert",
      "last_name": "F. Amelio",
      "permalink": "gilbert-f-amelio",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0016/7420/167420v2-max-150x150.jpg"],
          [[250,
            250],
           "assets/images/resized/0016/7420/167420v2-max-250x250.jpg"],
          [[400,
            400],
           "assets/images/resized/0016/7420/167420v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Arthur",
      "last_name": "\"Bobby\" Greenberg",
      "permalink": "arthur-bobby-greenberg",
      "image":
       {"available_sizes":
         [[[127,
            150],
           "assets/images/resized/0016/7424/167424v2-max-150x150.jpg"],
          [[212,
            250],
           "assets/images/resized/0016/7424/167424v2-max-250x250.jpg"],
          [[383,
            450],
           "assets/images/resized/0016/7424/167424v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Steven",
      "last_name": "Prelack",
      "permalink": "steven-prelack",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Jerald",
      "last_name": "Rome",
      "permalink": "jerald-rome",
      "image": null}},
   {"is_past": false,
    "title": "Scientific Advisory Board",
    "person":
     {"first_name": "Gilbert",
      "last_name": "S. Omenn",
      "permalink": "gilbert-s-omenn",
      "image": null}},
   {"is_past": false,
    "title": "Scientific Advisory Board",
    "person":
     {"first_name": "Irwin",
      "last_name": "Joseph Goldstein",
      "permalink": "irwin-joseph-goldstein",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Kevin",
      "last_name": "Freeman",
      "permalink": "kevin-freeman",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "John",
      "last_name": "Mauldin",
      "permalink": "john-mauldin",
      "image":
       {"available_sizes":
         [[[107,
            150],
           "assets/images/resized/0016/7421/167421v2-max-150x150.jpg"],
          [[178,
            250],
           "assets/images/resized/0016/7421/167421v2-max-250x250.jpg"],
          [[321,
            450],
           "assets/images/resized/0016/7421/167421v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Paul",
      "last_name": "Pressler",
      "permalink": "paul-pressler",
      "image":
       {"available_sizes":
         [[[120,
            140],
           "assets/images/resized/0016/7422/167422v2-max-150x150.jpg"],
          [[120,
            140],
           "assets/images/resized/0016/7422/167422v2-max-250x250.jpg"],
          [[120,
            140],
           "assets/images/resized/0016/7422/167422v2-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Marc",
      "last_name": "Rubin",
      "permalink": "marc-rubin",
      "image": null}},
   {"is_past": false,
    "title": "Scientific Advisory Board",
    "person":
     {"first_name": "Scott",
      "last_name": "L. Friedman",
      "permalink": "scott-l-friedman",
      "image": null}},
   {"is_past": true,
    "title": "CEO, Board of Directors",
    "person":
     {"first_name": "Theodore",
      "last_name": "D. Zucconi",
      "permalink": "theodore-d-zucconi",
      "image": null}},
   {"is_past": true,
    "title": "CFO",
    "person":
     {"first_name": "Anthony",
      "last_name": "Squeglia",
      "permalink": "anthony-squeglia",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$9.51M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2009/12/07/daily36-Pro-Pharmaceuticals-takes-another-325000-bite-of-Series-B.html",
    "source_description": "Pro-Pharmaceuticals takes another $325,000 bite of Series B",
    "raised_amount": 325000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2011/01/03/daily49-Pro-Pharmaceuticals-pulls-in-3M-from-stock-financings.html",
    "source_description": "Pro-Pharmaceuticals pulls in $3M from stock financings",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 6,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567312\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT",
    "raised_amount": 1800000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 2,
    "funded_day": 12,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567319\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT (this a difference tranche reported in body of article)",
    "raised_amount": 900000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 5,
    "funded_day": 13,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567319\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT",
    "raised_amount": 500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 6,
    "funded_day": 30,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567330\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT",
    "raised_amount": 325000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 10,
    "funded_day": 6,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567332\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT",
    "raised_amount": 310000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 4,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567334\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE",
    "raised_amount": 325000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567337\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE",
    "raised_amount": 325000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 2,
    "funded_day": 2,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "grant",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567368\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION",
    "raised_amount": 489000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 2,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "National Institutes of Health",
         "permalink": "national-institutes-of-health",
         "image":
          {"available_sizes":
            [[[150,
               23],
              "assets/images/resized/0025/4340/254340v1-max-150x150.png"],
             [[250,
               38],
              "assets/images/resized/0025/4340/254340v1-max-250x250.png"],
             [[391,
               60],
              "assets/images/resized/0025/4340/254340v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567338\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE",
    "raised_amount": 335000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 8,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567342\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND",
    "raised_amount": 310000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 4,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567344\u0026highlight=",
    "source_description": "PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE",
    "raised_amount": 570000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "10X Fund LP",
         "permalink": "10x-fund-lp",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "7 Wells Avenue",
    "address2": "",
    "zip_code": "02459",
    "city": "Newton",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "named former GlaxoSmithKline and Baylor University executive Peter G. Traber as president and CEO",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2011/03/07/daily35-Traber-named-CEO-at-Pro-Pharmaceuticals.html",
    "source_text": null,
    "source_description": "Traber named CEO at Pro-Pharmaceuticals",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "full of optimism, saying the company has turned around.",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily44-New-Pro-Pharmaceuticals-CEO-Traber-aims-to-steer-companys-recovery.html",
    "source_text": null,
    "source_description": "New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "full of optimism, saying the company has turned around.",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily44-New-Pro-Pharmaceuticals-CEO-Traber-aims-to-steer-companys-recovery.html",
    "source_text": null,
    "source_description": "New Pro-Pharmaceuticals CEO Traber aims to steer company's recovery",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 26,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1568451\u0026highlight=",
    "source_text": null,
    "source_description": "Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Lead candidate drug shown to prevent mucositis, a serious side effect of chemotherapy, in all 100 cancer patients treated.",
    "stoned_year": 2009,
    "stoned_month": 4,
    "stoned_day": 15,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567315\u0026highlight=",
    "source_text": null,
    "source_description": "Pro-Pharmaceuticals\u2019 DAVANAT\u00ae Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Announces liver fibrosis research collaboration with Mount Sinai School of Medicine.",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 21,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567362\u0026highlight=",
    "source_text": null,
    "source_description": "PRO-PHARMACEUTICALS \u0026 MOUNT SINAI SCHOOL OF MEDICINE ANNOUNCE NEW LIVER FIBROSIS RESEARCH COLLABORATION",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Pro-Pharmaceuticals\u2019 DAVANAT\u00ae Targets Galectin Proteins Secreted by Cancer Cells and Eliminates The Cancer\u2019s Ability to Evade the Immune System",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 20,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1567372\u0026highlight=",
    "source_text": null,
    "source_description": "THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS DISCOVER THAT DAVANAT\u00ae ENHANCES THE ABILITY OF ANTITUMOR T LYMPHOCYTES TO KILL TUMOR CELLS",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Galectin Therapeutics Announces Research Collaboration with University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease",
    "stoned_year": 2011,
    "stoned_month": 7,
    "stoned_day": 21,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1587501\u0026highlight=",
    "source_text": null,
    "source_description": "Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "10X Fund Issues Positive Statement Regarding Investment in Galectin Therapeutics",
    "stoned_year": 2011,
    "stoned_month": 8,
    "stoned_day": 5,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1593675\u0026highlight=",
    "source_text": null,
    "source_description": "10X Fund Issues Statement Regarding Investment in Galectin Therapeutics",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board",
    "stoned_year": 2011,
    "stoned_month": 11,
    "stoned_day": 2,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1624808\u0026highlight=",
    "source_text": null,
    "source_description": "Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Company launches Phase I/II trial in Europe with Ludwig Institute to Evaluate the Safety and Efficacy of Immunomodulatory Compound, GM-CT-01, with Peptide Vaccine",
    "stoned_year": 2011,
    "stoned_month": 12,
    "stoned_day": 8,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1637921\u0026highlight=",
    "source_text": null,
    "source_description": "Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}},
   {"description": "Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL",
    "stoned_year": 2011,
    "stoned_month": 12,
    "stoned_day": 16,
    "source_url": "http://phx.corporate-ir.net/phoenix.zhtml?c=135403\u0026p=irol-newsArticle\u0026ID=1640426\u0026highlight=",
    "source_text": null,
    "source_description": "Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Galectin Therapeutics",
      "permalink": "pro-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": 10400000.0,
   "valuation_currency_code": "USD",
   "pub_year": 2012,
   "pub_month": 3,
   "pub_day": 23,
   "stock_symbol": "NASDAQ:GALT"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0006/9261/69261v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0006/9261/69261v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0006/9261/69261v1-max-450x450.jpg"]],
    "attribution": null},
   {"available_sizes":
     [[[150,
        108],
       "assets/images/resized/0015/3340/153340v2-max-150x150.jpg"],
      [[250,
        181],
       "assets/images/resized/0015/3340/153340v2-max-250x250.jpg"],
      [[450,
        326],
       "assets/images/resized/0015/3340/153340v2-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}